ValiRx Plc - VAL201 Clinical Trial Full Data Results
VAL Mon, 30 Nov 2020, 03:30pm GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Dr Suzy Dilly, Chief Executive Officer discusses the VAL201 clinical trial results. The full dataset confirms VAL201 is a safe and well-tolerated drug candidate, demonstrating the potential of VAL201 for further development towards a treatment for patients with prostate cancer.